Biologics for Rheumatoid Arthritis Pain (BIORA-PAIN)

Rheumatoid Arthritis Clinical Trial

— BIORA-PAIN  

Official title:

Comparison of Abatacept With Tumor Necrosis Factor Inhibitors in the Treatment of Rheumatoid Arthritis Pain: A Phase IV Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04255134
• Other study ID #: 2019.0146
• Status: Completed
• Phase: Phase 4
• Start date: September 7, 2020
• Est. completion date: October 26, 2022

Study information

• Verified date: May 2023
• Source: St George's, University of London
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

It is increasingly recognized that although suppression of inflammation is a treatment goal in rheumatoid arthritis, many people who have control of their inflammation continue to experience pain. A number of studies have recently shown that by measuring further characteristics of pain in rheumatoid arthritis, e.g. neuropathic pain, quantitative sensory testing, compared with objective measures of inflammation, it is possible to acquire more detailed information about the level of pain in relation to inflammation that a patient with rheumatoid arthritis is experiencing, which could assist in developing their care.

In this study, the investigators will explore validated endpoints for pain including the Visual Analogue Scale for pain, neuropathic pain scores and quantitative sensory testing for pain.

The investigators will evaluate in a population-based study, the pain profile using the Visual Analog Scale (VAS), neuropathic pain assessment, quantitative sensory testing (QST) by pain pressure thresholds (PPT) in comparison to markers of inflammation in order to assess the difference in pain outcomes between baseline pre- and post- treatment in a population of participants with active Rheumatoid Arthritis treated with abatacept and Tumor Necrosis Factor (TNF) inhibitors respectively. All measures will be conducted systematically in the abatacept and TNF inhibitor groups pre- and post-treatment with respective biologic agents. Participants with active Rheumatoid Arthritis who may be eligible for biologic treatment will be screened for enrolment into the study.

Description:

Primary objective To examine: Pain characteristics in participants with active rheumatoid arthritis receiving abatacept biologic therapy versus TNF inhibitor therapy in the form of adalimumab.

To establish if there are differences in pain outcomes by patient reported scores, objective measures of pain using quantitative sensory testing and inflammatory markers in participants receiving biologic therapies for rheumatoid arthritis.

Population: The population being assessed in this study are participants with active rheumatoid arthritis with a disease activity score of greater than 5.1.

Intervention: Subjects will be randomized to treatment with abatacept or adalimumab for active rheumatoid arthritis

Comparison group: Abatacept is being compared to adalimumab therapy in the trial

Recruitment information / eligibility

• Status: Completed
• Enrollment: 18
• Est. completion date: October 26, 2022
• Est. primary completion date: October 26, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Active rheumatoid arthritis causing pain and functional impairment with DAS28 >5.1 -Has already received usual care for inflammatory arthritis including conventional DMARD therapy e.g. methotrexate, sulfasalazine, leflunomide, hydroxychloroquine on stable dose of csDMARD for at least 4 weeks prior to study drug initiation

• Willing to participate in the study over a 12-month period

• Desirably to have positive antibodies to cyclic citrullinated peptide (ACPA/CCP)

• Between 18 and 75 years of age

Exclusion Criteria:

• Pregnancy or pregnancy planned over next 12 months

• Current or previous unsuccessful use of the biologics abatacept or adalimumab

• Co-existing other autoimmune condition, e.g. systemic lupus erythematosus, -Sjogren's syndrome, connective tissue disease, fibromyalgia, osteoarthritis, gout

• Recent surgery in the last 3 months or imminent surgery in the next 12 months

• Unable to give informed consent

• Previous history of cancer in the last 5 years

• Previous history of multiple sclerosis

• Uncontrolled heart failure, hypertension or diabetes mellitus

• Known history of fibromyalgia or other chronic pain disorder

Related Conditions & MeSH terms

• Arthritis
• Arthritis, Rheumatoid
• Rheumatoid Arthritis

Intervention

Drug:
• Abatacept Injection
Subjects will be randomized to treatment with either abatacept or adalimumab
• Adalimumab Injection
Subjects will be randomized to treatment with either abatacept or adalimumab

Locations

Country	Name	City	State
United Kingdom	Hotung Centre for Musculoskeletal Diseases	London

Sponsors (1)

Lead Sponsor	Collaborator
St George's, University of London

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in the Visual Analogue Score for Pain	The Visual Analogue Score for Pain is a pain score which has a numerical rating scale from 0 to 10	0, 3, 6, 9, 12 months
Primary	Change in the Neuropathic pain questionnaire: PainDETECT	The painDETECT pain questionnaire is a numerical rated score for neuropathic pain	0, 3, 6, 9, 12 months
Primary	Change in Quantitative sensory testing	Quantitative sensory testing measures numerical values for pain in specific regions of testing	0, 3, 6, 9, 12 months
Secondary	Change in Blood markers	Pain biomarkers in serum	0, 3, 6, 9, 12 months